|Day Low/High||170.82 / 172.44|
|52 Wk Low/High||147.60 / 270.63|
Mydayis demonstrated improvements lasting up to 16 hours post-dose, beginning at 2 or 4 hours post-administration, compared to placebo, in total score on a skill-adjusted math test that measures attention in ADHD
Here are the activist investor's next potential targets.
Plus more from the biotechnology world on Wednesday, June 7.
Sage Therapeutics, Incyte and Shire were among the biotech movers in premarket trading on Thursday.
The study tested the drug on patients aged 12 years and older for 26 weeks.
Latest Research Supports Greater Understanding of the Evolving Needs of Adults with ADHD
Natpar is the first and only licensed recombinant human parathyroid hormone therapy for chronic hypoparathyroidism
Shire launches campaign to raise global awareness during World PI Week
New drug launches and late stage trials will be under the microscope as eight European pharmaceuticals companies report Q1 earnings starting next week.
PatientsLikeMe and Shire plc (LSE: SHP, NASDAQ: SHPG) have announced a new collaboration that will support the development of a patient-centered, real world health learning system that expands understanding of...
The Dax rose following a strong performance from the automotive sector, but both London and Paris slumped.
Shire data presentations at AAAAI 2017 reinforce the efficacy, safety, and tolerability of CUVITRU for primary immunodeficiency patients
BioCryst's Hereditary angioedema drug-trial results not compelling.
Current drugs approved to prevent and reduce the frequency of HAE swelling attacks require injections, so BioCryst's once-daily pill has the potential to be more convenient.